We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

119 hedge funds and large institutions have $491M invested in Supernus Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

85% more call options, than puts

Call options by funds: $4.93M | Put options by funds: $2.67M

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

59% more capital invested

Capital invested by funds: $309M → $491M (+$182M)

45% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 31

11% more funds holding

Funds holding: 107 → 119 (+12)

Holders
119
Holders Change
+12
Holders Change %
+11.21%
% of All Funds
3.17%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.19%
New
25
Increased
45
Reduced
31
Closed
13
Calls
$4.93M
Puts
$2.67M
Net Calls
+$2.26M
Net Calls Change
+$1.25M

Top Buyers

1
CCM
Consonance Capital Management
New York
+$33.7M
2
KCM
Kennedy Capital Management
Missouri
+$5.1M
3
ACM
Ashford Capital Management
Delaware
+$2.47M
4
CWG
C WorldWide Group
Denmark
+$2.36M
5
NC
Northpointe Capital
Michigan
+$2.15M

Top Sellers

1
AAP
Ardsley Advisory Partners
Connecticut
-$8.59M
2
A
Abingworth
United Kingdom
-$5.44M
3
MRM
Michael R. Murphy
-$4.26M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.41M
5
TC
TFS Capital
Pennsylvania
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$4.37M +$412K +43,588 +14%
Northern Trust
27
Northern Trust
Illinois
$3.78M +$202K +21,386 +7%
EAM
28
Eventide Asset Management
Massachusetts
$3.46M +$280K +29,600 +12%
PAM
29
Panagora Asset Management
Massachusetts
$2.82M +$902K +95,499 +69%
Allianz Asset Management
30
Allianz Asset Management
Germany
$2.73M +$75.8K +8,024 +4%
Two Sigma Investments
31
Two Sigma Investments
New York
$2.61M +$1.29M +137,033 +173%
Citadel Advisors
32
Citadel Advisors
Florida
$2.3M -$693K -73,312 -28%
ISL
33
Ingalls & Snyder LLC
New York
$2.04M +$509K +53,847 +47%
MC
34
Menta Capital
California
$2.04M +$711K +75,196 +81%
SIM
35
Spark Investment Management
New York
$2.01M +$641K +67,800 +69%
DCM
36
Driehaus Capital Management
Illinois
$1.94M +$1.52M +160,511 New
Geode Capital Management
37
Geode Capital Management
Massachusetts
$1.86M +$67.9K +7,185 +5%
RIM
38
Ranger Investment Management
Texas
$1.83M +$31.8K +3,370 +2%
FSA
39
Franklin Street Advisors
North Carolina
$1.77M -$403K -42,650 -23%
TC
40
TFS Capital
Pennsylvania
$1.74M -$2.55M -269,983 -65%
ZA
41
Zazove Associates
Nevada
$1.67M +$1.31M +138,429 New
GIP
42
Granite Investment Partners
California
$1.63M +$333K +35,230 +36%
AQR Capital Management
43
AQR Capital Management
Connecticut
$1.61M -$470K -49,700 -27%
AllianceBernstein
44
AllianceBernstein
Tennessee
$1.61M +$1.22M +129,070 +3,073%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$1.56M +$17.1K +1,809 +1%
RP
46
Reinhart Partners
Wisconsin
$1.46M -$91.9K -9,730 -7%
PC
47
Polar Capital
United Kingdom
$1.35M +$749K +79,245 +244%
CCM
48
Cadence Capital Management
Massachusetts
$1.34M +$9.73K +1,030 +0.9%
Stifel Financial
49
Stifel Financial
Missouri
$1.32M +$688K +72,827 +199%
SFM
50
Soros Fund Management
New York
$1.3M +$1.01M +107,308 New
1
2
3 4 5

SUPN Hedge Fund Activity: Q1 2015 in Review

119 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2015, worth a combined $491M — up 59% from $309M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SUPN positions and 13 closed out — a net gain of 12 holders — while 45 added to existing stakes and 31 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $33.7M. The largest seller was Ardsley Advisory Partners, cutting an estimated $8.59M.

  • 119 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2015, up from 107 in Q4 2014.
  • Funds reported $491M of Supernus Pharmaceuticals stock for Q1 2015, up 59% quarter-over-quarter.
  • 25 funds opened new Supernus Pharmaceuticals positions in Q1 2015 and 13 closed out, a net change of +12 holders.
  • The largest Supernus Pharmaceuticals buyer in Q1 2015 was Consonance Capital Management, an estimated $33.7M added.
  • The largest Supernus Pharmaceuticals seller in Q1 2015 was Ardsley Advisory Partners, an estimated $8.59M sold.

Based on aggregated 13F filings for Q1 2015.